Changes of Serum Insulin-like Growth Factor-2 Response to Negative Symptom Improvements in Schizophrenia Patients Treated with Atypical Antipsychotics

Abstract

Accumulating evidence suggests that a disruption of early brain development, in which insulin-like growth factor-2 (IGF-2) has a crucial role, may underlie the pathophysiology of schizophrenia. Our previous study has shown that decreased serum IGF-2 was correlated with the severity of psychopathology in patients with schizophrenia. Here we conducted a prospective observation trial to investigate the effects of atypical antipsychotics on serum IGF-2 level and its relationship with clinical improvements in schizophrenia patients. Thirty-one schizophrenia patients with acute exacerbation and 30 healthy individuals were recruited in this study. Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) and serum IGF-2 levels were determined using ELISA. We found that schizophrenia patients with acute exacerbation had lower serum IGF-2 levels than control individuals at baseline (P<0.05). After 2 months of atypical antipsychotic treatment, a significant improvement in each PANSS subscore and total score was observed in patients (all P<0.01), and the serum IGF-2 levels of patients were significantly increased compared with those at baseline (203.13±64.62 vs. 426.99±124.26 ng/mL; t =−5.044, P<0.001). Correlation analysis revealed that the changes of serum IGF-2 levels in patients were significantly correlated with the improvements of negative symptoms (r=−0.522, P=0.006). Collectively, our findings demonstrated changes of serum IGF-2 response to improvements of negative symptoms in schizophrenia patients treated with atypical antipsychotics, suggesting that serum IGF-2 might be a treatment biomarker for schizophrenia.

Keywords

schizophrenia / atypical antipsychotic / insulin-like growth factor-2 / negative symptoms

References

[1] OwenMJ, SawaA, MortensenPB. Schizophrenia. Lancet, 2016, 388(10039): 86-97

[2] MueserKT, McGurkSR. Schizophrenia. Lancet, 2004, 363(9426): 2063-2072

[3] LallyJ, MacCabeJH. Antipsychotic medication in schizophrenia: a review. Br Med Bull, 2015, 114(1): 169-179

[4] SanchezJPB, EllenbroekBA. Preclinical Effects of Antipsychotic Drugs. Curr Top Behav Neurosci, 2017, 34: 1-16

[5] KapurS, RemingtonG. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med, 2001, 52: 503-517

[6] Muller-SpahnF. Current use of atypical antipsychotics. Eur Psychiatry, 2002, 17(Suppl4): 377s-384s

[7] SolmiM, MurruA, PacchiarottiI, et al.. Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review. Ther Clin Risk Manag, 2017, 13: 757-777

[8] GallhoferB, BauerU, LisS, et al.. Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol, 1996, 6(Suppl2): S13-20

[9] KrakowskiMI, CzoborP, NolanKA. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients. J Clin Psychopharmacol, 2008, 28(5): 485-493

[10] van OsJ, KapurS, Schizophrenia. Lancet, 2009, 374(9690): 635-645

[11] ZhaoC, ZhuJ, LiuX, et al.. Structural and functional brain abnormalities in schizophrenia: A cross-sectional study at different stages of the disease. Prog Neuropsy-chopharmacol Biol Psychiatry, 2018, 83: 27-32

[12] CannonM, CaspiA, MoffittTE, et al.. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry, 2002, 59(5): 449-456

[13] BenarrochEE. Insulin-like growth factors in the brain and their potential clinical implications. Neurology, 2012, 79(21): 2148-2153

[14] O’KuskyJ, YeP. Neurodevelopmental effects of insulinlike growth factor signaling. Front Neuroendocrinol, 2012, 33(3): 230-251

[15] FromerM, RoussosP, SiebertsSK, et al.. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nat Neurosci, 2016, 19(11): 1442-1453

[16] PaiS, LiP, KillingerB, et al.. Differential methylation of enhancer at IGF2 is associated with abnormal dopamine synthesis in major psychosis. Nat Commun, 2019, 10(1): 2046

[17] AkanjiAO, OhaeriJU, Al-ShammriSA, et al.. Associations of blood levels of insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-3 in schizophrenic Arab subjects. Clin Chem Lab Med, 2007, 45(9): 1229-1231

[18] YangYJ, LuoT, ZhaoY, et al.. Altered insulin-like growth factor-2 signaling is associated with psychopathology and cognitive deficits in patients with schizophrenia. PLoS One, 2020, 15(3): e0226688

[19] LehmanAF, LiebermanJA, DixonLB, et al.. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry, 2004, 161(2Suppl): 1-56

[20] MortimerAM. Antipsychotic treatment in schizophrenia: atypical options and NICE guidance. Eur Psychiatry, 2003, 18(5): 209-219

[21] PeraltaV, de LeonJ, CuestaMJ. Are there more than two syndromes in schizophrenia? A critique of the positivenegative dichotomy. Br J Psychiatry, 1992, 161: 335-343

[22] DollfusS, LyneJ. Negative symptoms: History of the concept and their position in diagnosis of schizophrenia. Schizophr Res, 2017, 186: 3-7

[23] PalmerBW, DawesSE, HeatonRK. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychol Rev, 2009, 19(3): 365-384

[24] LeuchtS, CiprianiA, SpineliL, et al.. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 2013, 382(9896): 951-962

[25] MaherAR, MaglioneM, BagleyS, et al.. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA, 2011, 306(12): 1359-1369

[26] WoodwardND, PurdonSE, MeltzerHY, et al.. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol, 2005, 8(3): 457-472

[27] FernandezAM, Torres-AlemanI. The many faces of insulin-like peptide signalling in the brain. Nat Rev Neurosci, 2012, 13(4): 225-239

[28] RussoVC, GluckmanPD, FeldmanEL, et al.. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev, 2005, 26(7): 916-943

[29] LoganA, GonzalezAM, HillDJ, et al.. Coordinated pattern of expression and localization of insulin-like growth factor-II (IGF-II) and IGF-binding protein-2 in the adult rat brain. Endocrinology, 1994, 135(5): 2255-2264

[30] ShamblottMJ, LeungS, GreeneMW, et al.. Characterization of a teleost insulin-like growth factor II (IGF-II) gene: evidence for promoter CCAAT/enhancer-binding protein (C/EBP) sites, and the presence of hepatic C/EBP. Mol Mar Biol Biotechnol, 1998, 7(3): 181-190

[31] ChenDY, SternSA, Garcia-OstaA, et al.. A critical role for IGF-II in memory consolidation and enhancement. Nature, 2011, 469(7331): 491-497

[32] ChaseKA, RosenC, GinH, et al.. Metabolic and inflammatory genes in schizophrenia. Psychiatry Res, 2015, 225(1–2): 208-211

[33] HarrisonPJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain, 1999, 122(Pt4): 593-624

[34] HanQQ, ShenTT, WangF, et al.. Preventive and Therapeutic Potential of Vitamin C in Mental Disorders. Curr Med Sci, 2018, 38(1): 1-10

[35] ShuklaDK, ChiappelliJJ, SampathH, et al.. Aberrant Frontostriatal Connectivity in Negative Symptoms of Schizophrenia. Schizophr Bull, 2019, 45(5): 1051-1059

[36] BradyROJr., GonsalvezI, LeeI, et al.. Cerebellar-Prefrontal Network Connectivity and Negative Symptoms in Schizophrenia. Am J Psychiatry, 2019, 176(7): 512-520